Anti-N-methyl-D-aspartate receptor encephalitis associated with acute Toxoplasma gondii infection

A case report

Xiaotang Cai, MD\textsuperscript{a,b}, Hui Zhou, MD\textsuperscript{a,b,*}, Yongmei Xie, MD\textsuperscript{a,b}, Dan Yu, PhD\textsuperscript{a,b}, Zhiling Wang, MD\textsuperscript{a,b}, Haitao Ren, MD\textsuperscript{c}

Abstract

Rationale: Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis has been recognized as the most frequent autoimmune encephalitis in children. Several infectious agents have been implicated in anti-NMDA encephalitis.

Patient concerns: A previously healthy immunocompetent 9-year-old girl first presented with seizures, headaches, and vomiting. Cerebrospinal fluid and brain magnetic resonance imaging were normal. After one week onset, the patient gradually developed unexplained personality and behavior changes, accompanied by fever and seizures again. Repeated CSF analysis revealed a slightly lymphocytic predominant pleocytosis and positive anti-NMDAR antibody. A variety of pathogenic examinations were negative, except for positive toxoplasma IgM and IgG.

Diagnoses: The patient was diagnosed with anti-NMDA encephalitis associated with acute acquired toxoplasma gondii infection.

Interventions: The patient received 10 days azithromycin for treatment of acquired toxoplasma infection. The parents refuse immunotherapy because substantial recovery from clinical symptoms.

Outcomes: The patient was substantially recovered with residual mild agitation after therapy for acquired toxoplasma gondii infection. Two months later, the patient was completely devoid of symptoms, and the levels of serum IgM and IgG of toxoplasma gondii were decreased.

Lessons: Acquired toxoplasma gondii infection may trigger anti-NMDA encephalitis in children, which has not been reported previously. Clinicians should assess the possibility of toxoplasma gondii infection when evaluating a patient with anti-NMDA encephalitis.

Abbreviations: CSF = cerebrospinal fluid, CT = computerized tomography, EEG = electroencephalography, HIV = human immunodeficiency virus, MRI = magnetic resonance imaging, NMDAR = N-methyl-D-aspartate receptor, PCR = polymerase chain reaction.

Keywords: anti-NMDA receptor encephalitis, children, Toxoplasma gondii infection

1. Introduction

Since its first description in 2007, anti-NMDAR (anti-N-methyl-D-aspartate) receptor encephalitis has been recognized as autoimmune encephalitis that is mediated by antibodies recognizing the NR1 subunit of NMDAR and attenuating NMDAR function. This form of encephalitis is characterized by various symptoms, such as memory loss, confusion, emotional disturbances, psychosis, dyskinesia, decrease in speech intelligibility, and seizure.\textsuperscript{[1–7]} Florence et al.\textsuperscript{[8]} reported the first pediatric patient (age < 18 years) with anti-NMDA receptor encephalitis. Although the clinical manifestation of anti-NMDAR encephalitis in children and adults was similar, most children did not have underlying tumors.\textsuperscript{[6–7]} This autoimmune response to the NR1 subunit of the NMDA receptor is possibly triggered by various infectious agents. Previous reports have suggested that anti-NMDAR encephalitis may be associated with the herpes simplex virus, mycoplasma pneumoniae, measles virus, mumps, and group A hemolytic streptococcus.\textsuperscript{[6–7]}

Although Toxoplasma gondii infects a large proportion of the human population, acute acquired T gondii infection is usually asymptomatic or accompanied by lymphadenopathy in immunocompetent children. In rare cases it can cause severe neurological disease.\textsuperscript{[8]} To date, anti-NMDAR encephalitis associated with acute acquired T gondii infection has not been...
reported. In this report, we present the case of an immunocompetent girl who was diagnosed with anti-NMDAR encephalitis associated with acute *T. gondii* infection.

2. Case report

A 9-year-old previously healthy girl was admitted following 5 seizures accompanied by vomiting and headache in 1 day. There was no history of fever, trauma, infection, vaccination, or drug usage. The neurological examination was normal. Laboratory testing revealed normal erythrocyte sedimentation rate, complete blood count, and biochemistry (blood gas analysis, blood electrolyte, blood ammonia, and blood lactic acid). Chest radiography and ophthalmological examination results were normal. Brain computerized tomography (CT) and magnetic resonance imaging (MRI) were normal. Virus serologic test results for hepatitis A, B, and C, herpes simplex, Epstein–Barr virus, cytomegalovirus, varicella, measles, rubella, mumps, and human immunodeficiency virus (HIV) were negative. Blood culture and tuberculin skin test results were negative. Blood cellular and humoral immunity were normal. Cerebrospinal fluid (CSF) analysis and bacterial culture were negative. Electroencephalography (EEG) was normal. She had complete recovery and was discharged 3 days later.

One week after being discharged home, the girl developed unexplained personality and behavior changes including agitation, amnesia, periods of hyperexcitability, and intolerable paroxysmal skin itching. The patient was readmitted to the pediatric neurological unit, and her medical history was updated with information that the girl had played with neighbor’s dog in the previous 6 months. The neurological examination was normal and the skin was free of rash. CSF analysis revealed a lymphocytic pleocytosis (18 × 10^6/L) with 87% lymphocytes and normal glucose and protein levels. CSF polymerase chain reaction test for HSV was negative. Toxicological screening was negative. Testing for antibodies to cell surface or synaptic proteins and oligoclonal bands of immunoglobulin (Ig)G was conducted by Peking Union Medical College Hospital. A repeat brain MRI was normal. The EEG demonstrated 14 Hz sporadic positive spikes without diffuse slow activity, and epileptiform discharges. Serum serologic tests for adenovirus, Epstein–Barr virus, Coxsackie virus, rubella virus, cytomegalovirus, and enterovirus were negative. Mycoplasma antibody was negative. A *T. gondii* serologic test result was positive (Table 1). Humoral and cellular immunity tests were normal. After the third day of her readmittance, the patient developed high fever and experienced generalized convulsions for 1 minute. The patient then began a 10-day course of oral azithromycin. Two weeks after admission, the patient had substantially recovered with residual mild agitation remaining. Subsequently, a positive result for NMDA receptor antibodies was received (positive antibody reactivity in CSF (Fig. 1), weak positive antibody reactivity in serum, other paraneoplastic antibodies, and oligoclonal bands of IgG were negative). Because of her substantial recovery from clinical symptoms, the patient’s parents refused immunotherapy including gamma globulin and methyl prednisone. After completing tumor screening via chest and abdomen contrast-enhanced CT and pelvic ultrasound, for which the results were normal, the patient was discharged. She received follow-up 2 months later, and presented with complete resolution of symptoms. Toxoplasma gondii serologic test results were rechecked and the levels of serum IgM and IgG had declined notably at this 2-month follow-up (Table 1).

3. Discussion

In this patient, the clinical presence of psychiatric symptoms, seizure, and paresthesia, accompanied by positive NMDA receptor antibodies in CSF and serum, led to consideration of a diagnosis of anti-NMDAR encephalitis.[1–4] Anti-NMDAR encephalitis was first described in a young woman with ovarian teratoma and initially found in association with thymomas and other tumors. However, an increasing number of cases have been reported in children without tumors.[5–7] The NMDA receptor is found in dense concentrations in the hippocampus, which is involved in spatial learning and long-term potentiation, both of which are key features of memory formation.[11,9–11] The clinical finding that patients with anti-NMDAR encephalitis experience persistent amnesia is consistent with the NMDA receptor’s role in learning and memory.[11,12] It has been hypothesized that sustained hypoactivity of the NMDAR receptor is thought to underlie the pathogenesis of schizophrenia and hyperactivity linked to psychosis, Alzheimer’s disease, and now autoimmune encephalitis.[11,10,11] The mechanism that begins the autoimmune process is currently unclear.

Approximately 50% of these patients have a tumor that was suspected to have triggered the syndrome (most frequently an ovarian teratoma)[12]; in contrast, in the pediatric population, the condition is most commonly diagnosed in the absence of tumors.[11] Although the phenotype in children has the same characteristic as that of adults, there are significant differences with respect to the association with tumor.[12,13] The mechanism

![Figure 1. Using indirect immunofluorescence method, an anti-NMDA receptor IgG antibody was detected to be positive in the patient’s CSF. CSF = cerebrospinal fluid, Ig = immunoglobulin, NMDA = N-methyl-D-aspartate receptor.](Image 340x583 to 569x760)

| Table 1 | Toxoplasma gondii serologic test results. |
|---------|------------------------------------------|
| Date of testing | IgM, AU/mL | IgG, IU/mL |
| Initial | 11.2 | >400 |
| 2 months later | 6.3 | 181 |

*Toxoplasma gondii* serologic IgM: Negative <6.0 suspicious 6.0–8.0 positive >8.0.

*Toxoplasma gondii* serologic IgG: Negative <7.2 suspicious 6.0–8.0 positive >8.0.

Ig = immunoglobulin.
that triggers the autoimmune process may differ between adults and children.

Recent reports suggest that postinfectious immune-mediated etiology may be linked to anti-NMDA receptor encephalitis without a tumor association. Various infectious agents can damage the blood–brain barrier and trigger a synaptic inflammatory response. Sutcu et al. reported pediatric cases of post-herpes simplex virus encephalitis relapses associated with autoantibodies against NMDA receptors. Prins et al. reported that 30% of patients with simplex herpes virus encephalitis had NMDAR antibodies detected in serum or CSF. In some patients with anti-NMDAR encephalitis, there are associations with other pathogens, including Mycoplasma pneumoniae and influenza virus A and B, Chlamydia pneumoniae, Bordetella pertussis, Bordetella parapertussis, and denseovirus, varicella zoster virus, and Epstein–Barr virus. Toxoplasma gondii infection may trigger anti-NMDAR encephalitis; this possibility has not been reported previously.

In our case, brain viral infection seems unlikely because viral screenings were negative and cranial MRI studies were normal. Because our patient was positive for CSF T gondii antibodies and psychosis is an atypical symptom of toxoplasmonic encephalitis, we need to distinguish psychiatric disorders induced by T gondii. Toxoplasmal encephalitis is a common opportunistic infection in patients with acquired immunodeficiency syndrome that is rarely observed in patients with normal immune function. A presumptive diagnosis of toxoplasmonic encephalitis requires the following 3 stipulations: clinical manifestations, positive IgG for blood T gondii, and characteristic neuroradiological abnormalities.

Typical patients with toxoplasmal encephalitis present with fever, headache, seizures, psychosis, altered mental status, and focal neurologic symptoms. Goitia reported the clinical characteristics of cerebral toxoplasmosis in patients with HIV infection as focal neurological deficits (73.07%), signs of intracranial hypertension (69.20%), meningeal syndrome (59.40%), seizures (57.69%), and consciousness disorders (30.80%). Neuroimaging studies are crucial in the diagnosis of toxoplasmosis encephalitis. Toxoplasma gondii cysts can invade the central nervous system, causing perivascular inflammation that gradually progresses to necrotizing encephalitis. Brain MRI reveals multiple ring-enhancing lesions surrounded by edema. Lesions are most often located in the subcortical white matter, the basal ganglia, or the brainstem. In our case, the patient’s innate immune state was normal, serum HIV test was negative, brain MRI images were normal, and CSF examination was nearly normal; clinical manifestations consisted of psychiatric symptoms, seizure, and paresthesia without focal neurological symptoms. Therefore, we do not believe that there was reasonable evidence by which to diagnose toxoplasmosis encephalitis.

Psychosis may occur in systemic toxoplasmic infection, but not as a major clinical manifestation. At the same time, some investigations of patients with psychosis (i.e., schizophrenia, bipolar disorder, and depression) have revealed a higher prevalence of IgG antibodies to T gondii compared to neurotypical individuals. The underlying mechanism that links T gondii infection and psychiatric disorders is unclear. Huber et al. suggested that toxoplasmosis might induce elevated levels of dopamine in the mouse brain. Animal research shows that T gondii infection may trigger an inflammatory response and impair the blood–brain barrier. Recently, Hayes et al. found increased inflammatory molecules in patients with psychiatric disorders induced by toxoplasma infection, which suggests that the immune system participates in the psychiatric disorders induced by T gondii infection. In our case, we found anti-NMDA receptor antibodies in CSF; as such, we speculate that anti-NMDA receptor antibodies may be one of the possible causes of psychiatric symptoms induced by toxoplasma infection. We suggest that CSF should be tested for anti-NMDA receptor antibodies in patients with acquired toxoplasma infection who present with psychiatric symptoms. This speculation needs to be validated in more patients with toxoplasma infection.

The immunoreaction of NMDAR antibodies is reversible, and the immune response is self-limiting. Titular et al. reported 577 cases of anti-NMDAR encephalitis, 29 cases were not treated with immunotherapy or surgery, and 70% had a good outcome. Spontaneous improvement has also been described by other authors. In our patient, the clinical symptoms were atypical; the level of anti-NR1 receptor antibodies was not notably high (antibody reactivity in CSF was positive, and there was weak positivity for the antibody in serum) and after anti-T gondii treatment by oral azithromycin, the patient recovered without immunotherapy.

Taken together, the biphasic course of symptoms of our patient, along with CSF positive for NMDAR antibodies, a positive T gondii serologic test, no additional changes in the brain MRI, and improved clinical symptoms after anti-T gondii treatment suggested that this patient with acquired T gondii infection may have contracted anti-NMDAR encephalitis. This possible link between both disorders also suggests a postinfectious immune-mediated etiology. Future studies should address these issues in clinical trials.

4. Conclusion

Anti-NMDA receptor encephalitis in children is generally associated with a postinfection state rather than the presence of tumor. Acute T gondii infection could trigger anti-NMDA receptor encephalitis. Appropriate treatment helps relieve symptoms and foster a good prognosis.

Acknowledgments

The authors thank Dr Ren Haitao for blood and CSF anti-NMDAR antibodies test. We would like to thank Editage (www.editage.com) for English language editing.

References

[1] Kahn I, Helman G, Vanderver A, et al. Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis. J Child Neurol 2017;32:243–5.
[2] Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011;10:63–74.
[3] Titular MJ, McCracken L, Gablond I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013;12:157–65.
[4] Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36.
[5] Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 2009;66:11–8.
[6] Armangue T, Titulaer MJ, Malaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr 2013;162:850–6.
[7] Goldberg EM, Titulaer M, de Blank PM, et al. Anti-N-methyl-D-aspartate receptor-mediated encephalitis in infants and toddlers: case report and review of the literature. Pediatr Neurol 2014;50:181–4.
[8] Ho EL, Marra CM. Central nervous system diseases due to opportunistic and coinfections. Semin Neurol 2014;34:61–9.
[9] Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 2007;61:25–36.
[10] BlissTV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993;361:31–9.
[11] Newcomer JW, Farber NB, Olney JW. NMDA receptor function, memory, and brain aging. Dialogues Clin Neurosci 2000;2:219–32.
[12] Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091–8.
[13] Ryan N. Anti-N-methyl-D-aspartate receptor-mediated encephalitis: recent advances in diagnosis and treatment in children. Curr Probl Pediatr Adolesc Health Care 2016;46:58–61.
[14] Miya K, Takahashi Y, Mori H. Anti-NMDAR autoimmune encephalitis. Brain Dev 2014;36:645–52.
[15] Thomas L, Mailles A, Desestret V, et al. Autoimmune N-methyl-D-aspartate receptor encephalitis is a differential diagnosis of infectious encephalitis. J Infect 2014;68:419–25.
[16] Sutcu M, Aktürk H, Somer A, et al. Role of autoantibodies to N-methyl-D-aspartate (NMDA) receptor in relapsing herpes simplex encephalitis: a retrospective, one-center experience. J Child Neurol 2016;31:545–50.
[17] Pruss H, Finkz C, Holtz M, et al. NMDA receptor antibodies in herpes simplex encephalitis. Ann Neurol 2012;61:902–11.
[18] Gable MS, Gavali S, Radner A, et al. Anti-NMDA receptor encephalitis: report of ten cases and comparison with viral encephalitis. Eur J Clin Microbiol Infect 2009;28:1421–9.
[19] Pruss H, Dalmau J, Harms L, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. Neurology 2010;75:1735–9.
[20] Phan TG, Messacar K, Dominguez SR, et al. A new nosophirus in cerebrospinal fluid from a case of anti-NMDA-receptor encephalitis. Arch Virol 2016;161:3231–5.
[21] Solis N, Salazar L, Hasbun R. Anti-NMDA receptor antibody encephalitis with concomitant detection of Varicella zoster virus. J Clin Virol 2016;83:26–8.
[22] Xu CL, Liu L, Zhao WQ, et al. Anti-N-methyl-D-aspartate receptor encephalitis with serum anti-thyroid antibodies and IgM antibodies against Epstein–Barr virus viral capsid antigen: a case report and one year follow-up. BMC Neurol 2011;11:149.
[23] Monroe JM, Buckley PF, Miller BJ. Meta-analysis of anti-toxoplasma gondii IgM antibodies in acute psychosis. Schizophr Bull 2015;41:989–98.
[24] Zhu S. Psychosis may be associated with toxoplasmosis. Med Hypotheses 2009;73:799–801.
[25] Sakamoto N, Maeda T, Mikita K, et al. Clinical presentation and diagnosis of toxoplastic encephalitis in Japan. Parasitol Int 2014;63:701–4.
[26] Goita D, Karambe M, Dembélé JP, et al. Cerebral toxoplasmosis during AIDS in the infectious diseases department of Point-G Teaching Hospital, Bamako, Mali. Mali Med 2012;27:47–50.
[27] Mahadevan A1, Ramalingasah AH, Parthasarathy S, et al. Neuropathological correlate of the "concentric target sign" in MRI of HIV-associated cerebral toxoplasmosis. J Magn Reson Imaging 2013;38:488–95.
[28] Hayes LN, Severance EG, Leek JT, et al. Inflammatory molecular signature associated with infectious agents in psychosis. Schizophr Bull 2014;40:963–72.
[29] Huber M, Kirchner E, Karner M, et al. Delusional parasitosis and the dopamine transporter. A new insight of etiology? Med Hypotheses 2007;68:1351–8.
[30] Wandinger KP, Saschenbrecker S, Stoecker W, et al. Anti-NMDA-receptor encephalitis: a severe, multistage, treatable disorder presenting with psychosis. J Neuroimmunol 2011;231:86–91.
[31] Izuka T, Sakai F, Ide T, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology 2008;70:504–11.